Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia.

[1]  P. Lestage,et al.  Inhibition of l-homocysteic acid and buthionine sulphoximine-mediated neurotoxicity in rat embryonic neuronal cultures with α-lipoic acid enantiomers , 2000, Brain Research.

[2]  P. Mcgeer,et al.  Brain inflammation in Alzheimer disease and the therapeutic implications. , 1999, Current pharmaceutical design.

[3]  P. Riederer,et al.  High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression , 1999 .

[4]  P. Tariot,et al.  Diabetes and Dementia in Long‐Term Care , 1999, Journal of the American Geriatrics Society.

[5]  T. Harris,et al.  Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance , 1999, Neurology.

[6]  B. Flynn,et al.  Pharmacologic Management of Alzheimer Disease Part II: Antioxidants, Antihypertensives, and Ergoloid Derivatives , 1999, The Annals of pharmacotherapy.

[7]  N. Sacktor.  A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment , 1998, Neurology.

[8]  L. Friedhoff,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study , 1998, European Neuropsychopharmacology.

[9]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[10]  T. Luther,et al.  Advanced Glycation End Product-Induced Activation of NF-κB is Suppressed by α-Lipoic Acid in Cultured Endothelial Cells , 1997, Diabetes.

[11]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[12]  J. Thome,et al.  Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.

[13]  A. Klip,et al.  Stimulation of Glucose Uptake by the Natural Coenzyme α-Lipoic Acid/Thioctic Acid: Participation of Elements of the Insulin Signaling Pathway , 1996, Diabetes.

[14]  G. Martin,et al.  Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. , 1996, Molecular and chemical neuropathology.

[15]  L. Packer,et al.  alpha-Lipoic acid as a biological antioxidant. , 1995, Free radical biology & medicine.

[16]  M. Albert,et al.  Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease , 1994, Neurology.

[17]  K. Davis,et al.  A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.

[18]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[19]  L. Packer.  Interactions among Antioxidants in Health and Disease: Vitamin E and Its Redox Cycle , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[20]  S. Hoyer.  Abnormalities of Glucose Metabolism in Alzheimer's Disease , 1991, Annals of the New York Academy of Sciences.

[21]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[22]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[23]  U. Schmidt,et al.  Chemie und Biochemie der α-Liponsäure , 1965 .

[24]  P. Riederer,et al.  Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress , 1998, Journal of Neural Transmission.

[25]  K. Hager,et al.  INTERDISZIPLINARE GEDACHTNISSPRECHSTUNDE HANNOVER , 1998 .

[26]  P. Riederer,et al.  Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.

[27]  T. Luther,et al.  Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. , 1997, Diabetes.

[28]  L. Packer,et al.  Neuroprotection by the metabolic antioxidant alpha-lipoic acid. , 1997, Free radical biology & medicine.

[29]  L. Packer,et al.  Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid , 1997 .

[30]  L. Frölich,et al.  Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? , 1995, Journal of neural transmission. Supplementum.